LUND, Sweden – Cellevate AB, an innovative biotech company that develops the next generation of cell culture systems designed to revolutionize biomanufacturing, celebrated last week the inauguration of its new, larger premises at Medicon Village in Lund, Sweden. The highlight of the event was the official opening of the internal upstream bioprocessing cell culture facility, which was led by Prof. Lars Montelius, PhD who is one of the founders of Cellevate, Professor Emeritus at Lund University, and Co-Chair of the Steering Group of the Advanced Materials Initiative (AMI 2030).
“The relocation to larger facility is one of the stepping stones for Cellevate towards the launch of Cellevat3d™ microcarriers in upstream bioprocessing applications in 2024. We are particularly excited about having our own upstream bioprocessing cell culture laboratory for the development and optimization of the use of Cellevat3d™ microcarriers in process development and production of novel biotherapies. Prof. Lars Montelius inaugurating the new premises marked a new beginning for the commercialization of Cellevat3d™ nanofiber-based products in industrial applications“, says Laura Chirica, CEO, Cellevate.
For more information, please contact:
Laura Chirica, PhD
CEO Cellevate
Email: laura.chirica@cellevate.com
About Cellevate
Cellevate is a spin out from NanoLund – a world leading nanomaterial academic center, part of Lund University in Sweden. The company develops and markets products based on a proprietary nanofiber-based platform – the Cellevat3d™ – a game-changing, green and sustainable, deep-tech innovation for the biopharmaceutical industry. This platform allows for an industrial-scale production of nanofiber materials – “microcarriers” – with unparalleled surface area for cell growth, reproducibility and customization, which ultimately lead to an improved biomanufacturing productivity and process economy. Cellevat3d™ microcarriers products are designed as an integrated part of upstream bioprocess solutions, starting with laboratory testing of cell lines followed by pilot and large-scale batch production of novel classes of biological therapies, including cell- and gene therapies and vaccines. Cellevat3d™ microcarriers launch is planned for 2024.
For more information, please visit www.cellevate.com.
